A Phase 3b/4 Randomized, Open-label, Efficacy Assessor Blinded Study, Comparing the Safety and Assessor Blinded Efficacy of Upadacitinib to Dupilumab in Subjects with Moderate to Severe Atopic Dermatitis (Level-Up).
Datos básicos
Documentos
- No hay documentos
Grupos
Financiadores - Promotores
ABBVIE DEUTSCHLAND GMBH & CO. KG
Cita
A Phase 3b/4 Randomized, Open-label, Efficacy Assessor Blinded Study, Comparing the Safety and Assessor Blinded Efficacy of Upadacitinib to Dupilumab in Subjects with Moderate to Severe Atopic Dermatitis (Level-Up). (M23-696). ABBVIE DEUTSCHLAND GMBH & CO. KG. 2023IP:MERCEDES RODRÍGUEZ SERNA.
Portal de investigación